Details for Patent: 7,687,052
Which drugs does patent 7,687,052 protect, and when does it expire?
Patent 7,687,052 protects AMYVID and is included in one NDA.
This patent has fifty-one patent family members in thirty-three countries.
Summary for Patent: 7,687,052
| Title: | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
| Abstract: | This invention relates to a method of imaging amyloid deposits and to styrylpyridine compounds, and methods of making radiolabeled styrylpyridine compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits. |
| Inventor(s): | Hank F. Kung, Mei-Ping Kung |
| Assignee: | University of Pennsylvania Penn |
| Application Number: | US11/727,401 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,687,052 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 7,687,052
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-001 | Apr 6, 2012 | DISCN | Yes | No | 7,687,052 | ⤷ Start Trial | Y | Y | PET TO ESTIMATE AMYLOID BETA NEURITIC PLAQUE DENSITY IN ADULTS WITH COGNITIVE IMPAIRMENT: -EVALUATION OF ALZHEIMER’S DISEASE AND OTHER CAUSES OF COGNITIVE DECLINE -SELECTION OF PATIENTS WHO ARE INDICATED FOR AMYLOID BETA-DIRECTED THERAPY | ⤷ Start Trial | ||
| Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-004 | Oct 13, 2023 | RX | Yes | Yes | 7,687,052 | ⤷ Start Trial | Y | Y | PET TO ESTIMATE AMYLOID BETA NEURITIC PLAQUE DENSITY IN ADULTS WITH COGNITIVE IMPAIRMENT: -EVALUATION OF ALZHEIMER’S DISEASE AND OTHER CAUSES OF COGNITIVE DECLINE -SELECTION OF PATIENTS WHO ARE INDICATED FOR AMYLOID BETA-DIRECTED THERAPY | ⤷ Start Trial | ||
| Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-002 | Apr 6, 2012 | DISCN | Yes | No | 7,687,052 | ⤷ Start Trial | Y | Y | PET TO ESTIMATE AMYLOID BETA NEURITIC PLAQUE DENSITY IN ADULTS WITH COGNITIVE IMPAIRMENT: -EVALUATION OF ALZHEIMER’S DISEASE AND OTHER CAUSES OF COGNITIVE DECLINE -SELECTION OF PATIENTS WHO ARE INDICATED FOR AMYLOID BETA-DIRECTED THERAPY | ⤷ Start Trial | ||
| Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-003 | Apr 6, 2012 | RX | Yes | Yes | 7,687,052 | ⤷ Start Trial | Y | Y | PET TO ESTIMATE AMYLOID BETA NEURITIC PLAQUE DENSITY IN ADULTS WITH COGNITIVE IMPAIRMENT: -EVALUATION OF ALZHEIMER’S DISEASE AND OTHER CAUSES OF COGNITIVE DECLINE -SELECTION OF PATIENTS WHO ARE INDICATED FOR AMYLOID BETA-DIRECTED THERAPY | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,687,052
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1999109 | ⤷ Start Trial | C300600 | Netherlands | ⤷ Start Trial |
| European Patent Office | 1999109 | ⤷ Start Trial | CA 2013 00035 | Denmark | ⤷ Start Trial |
| European Patent Office | 1999109 | ⤷ Start Trial | PA2013016 | Lithuania | ⤷ Start Trial |
| European Patent Office | 1999109 | ⤷ Start Trial | 92232 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 1999109 | ⤷ Start Trial | C20130016 00076 | Estonia | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
